| Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson PLoS computational biology 9 (3), e1002959, 2013 | 119 | 2013 |
| Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: a historical prospective study A Levi, E Cohen, M Levi, E Goldberg, M Garty, I Krause European journal of internal medicine 25 (10), 951-955, 2014 | 83 | 2014 |
| Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model Z Symon, M Levi, WD Ensminger, DE Smith, TS Lawrence International Journal of Radiation Oncology* Biology* Physics 50 (2), 473-478, 2001 | 66 | 2001 |
| Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis M Levi, S Grange, N Frey The Journal of Clinical Pharmacology 53 (2), 151-159, 2013 | 55 | 2013 |
| Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application M Levi, DA Dempsey, NL Benowitz, LB Sheiner Journal of pharmacokinetics and pharmacodynamics 34, 23-34, 2007 | 45 | 2007 |
| Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects F Schneider, L Erisson, H Beygi, M Bradbury, O Cohen‐Barak, ... British Journal of Clinical Pharmacology 84 (10), 2422-2432, 2018 | 36 | 2018 |
| Modeling viral kinetics and treatment outcome during alisporivir interferon‐free treatment in hepatitis C virus genotype 2 and 3 patients J Guedj, J Yu, M Levi, B Li, S Kern, NV Naoumov, AS Perelson Hepatology 59 (5), 1706-1714, 2014 | 35 | 2014 |
| Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin’s lymphoma (NHL) patients. J Li, M Levi, JE Charoin, N Frey, T Kheoh, S Ren, M Woo, A Joshi, ... Blood, The Journal of the American Society of Hematology 110 (11), 2371-2371, 2007 | 34 | 2007 |
| Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy X Xu, D Khadzhynov, H Peters, RL Chaves, K Hamed, M Levi, N Corti British journal of clinical pharmacology 83 (3), 498-509, 2017 | 29 | 2017 |
| Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys M Levi, JA Knol, WD Ensminger, SJ DeRemer, C Dou, SM Lunte, ... Drug metabolism and disposition 30 (12), 1425-1430, 2002 | 29 | 2002 |
| Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives M Levi, B Yagen, M Bialer Pharmaceutical research 14, 213-217, 1997 | 29 | 1997 |
| Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine JB Fiedler‐Kelly, O Cohen‐Barak, DN Morris, E Ludwig, M Rasamoelisolo, ... British Journal of Clinical Pharmacology 85 (12), 2721-2733, 2019 | 24 | 2019 |
| Population pharmacokinetics of nicotine and its metabolites I. Model development M Levi, DA Dempsey, NL Benowitz, LB Sheiner Journal of pharmacokinetics and pharmacodynamics 34, 5-21, 2007 | 23 | 2007 |
| Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid O Spiegelstein, DL Kroetz, RH Levy, B Yagen, SI Hurst, M Levi, ... Pharmaceutical research 17, 216-221, 2000 | 20 | 2000 |
| Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data M Levi, N Frey, S Grange, D Schwab, T Woodworth Ann Rheum Dis 67 (Suppl II), 192, 2008 | 15 | 2008 |
| Effect of fremanezumab monthly and quarterly doses on efficacy responses J Fiedler‐Kelly, J Passarell, E Ludwig, M Levi, O Cohen‐Barak Headache: The Journal of Head and Face Pain 60 (7), 1376-1391, 2020 | 13 | 2020 |
| A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg‐IFN on Hepatitis C Virologic Response THT Nguyen, F Mentré, M Levi, J Yu, J Guedj Clinical Pharmacology & Therapeutics 96 (5), 599-608, 2014 | 13 | 2014 |
| Disposition of WR‐1065 in the liver of tumor‐bearing rats following regional vs systemic administration of amifostine M Levi, SJ DeRemer, C Dou, WD Ensminger, DE Smith Biopharmaceutics & drug disposition 25 (1), 27-35, 2004 | 11 | 2004 |
| Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling … O Cohen-Barak, A Radivojevic, A Jones, J Fiedler-Kelly, M Gillespie, ... Cephalalgia 41 (10), 1065-1074, 2021 | 9 | 2021 |
| Characterization of the time-varying clearance of rituximab in non-Hodgkin’s lymphoma patients using a population pharmacokinetic analysis M Levi, J Li, N Frey, T Kheoh, S Ren, M Woo, A Joshi, N Valente, N Jumbe, ... American Conference on Pharmacometrics, 9-12, 2008 | 8 | 2008 |
Jeremie GuedjResearcher at the French Institute of Health and Medical Research (INSERM)Verified email at inserm.fr